Pharma Mar (OTCMKTS:PHMMF) Raised to “Hold” at Zacks Research

Pharma Mar (OTCMKTS:PHMMF) was upgraded by analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other equities analysts also recently weighed in on the stock. Chardan Capital raised shares of Pharma Mar to a “strong-buy” rating in a report on Tuesday, June 9th. BTIG Research initiated coverage on shares of Pharma Mar in a report on Thursday, April 23rd. They issued a “buy” rating on the stock. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy”.

Pharma Mar Price Performance

Shares of OTCMKTS:PHMMF opened at $79.49 on Monday. The company’s 50-day moving average is $104.27 and its 200 day moving average is $94.45. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.02 and a quick ratio of 2.44. Pharma Mar has a fifty-two week low of $77.41 and a fifty-two week high of $110.40.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.